PCRX VS IRWD Stock Comparison

PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilitySentiment
PerformanceAnalyst Price TargetsTechnicalsEarningsProfitVolatilitySentiment

Performance

PCRX
10/100

PCRX returned -42.37% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

IRWD
53/100

IRWD returned -20.45% in the last 12 months. Based on SPY's performance of -21.13%, its performance is above average giving it a score of 53 of 100.

Analyst Price Targets

PCRX
67/100

16 analysts offer 12-month price targets for PCRX. Together, they have an average target of 57.5, the most optimistic target put PCRX at 63 within 12-months and the most pessimistic has PCRX at 52.

IRWD
66/100

11 analysts offer 12-month price targets for IRWD. Together, they have an average target of 16, the most optimistic target put IRWD at 16 within 12-months and the most pessimistic has IRWD at 16.

Technicals

PCRX
21/100

PCRX receives a 21 of 100 based on 14 indicators. 2 are bullish, 10 are bearish.

IRWD
11/100

IRWD receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

PCRX
10/100

PCRX has missed earnings 8 times in the last 20 quarters.

IRWD
20/100

IRWD has missed earnings 4 times in the last 20 quarters.

Profit

PCRX
55/100

Out of the last 20 quarters, PCRX has had 12 profitable quarters and has increased their profits year over year on 8 of them.

IRWD
71/100

Out of the last 20 quarters, IRWD has had 16 profitable quarters and has increased their profits year over year on 9 of them.

Volatility

PCRX
45/100

PCRX has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

IRWD
49/100

IRWD has had a lower than average amount of volatility over the last 12 months giving it a score of 49 of 100.

Sentiment

PCRX

"Sentiment" not found for PCRX

IRWD
67/100

IRWD had a bullish sentiment score of 67.17% across Twitter and StockTwits over the last 12 months. It had an average of 7.07 posts, 4.13 comments, and 5.41 likes per day.

All score calculations are broken down here to help you make more informed investing decisions

Pacira BioSciences, Inc. Common Stock Summary

Nasdaq / PCRX
Healthcare
Drug Manufacturers - Specialty & Generic
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.

Ironwood Pharmaceuticals, Inc. - Class A Summary

Nasdaq / IRWD
Healthcare
Drug Manufacturers - Specialty & Generic
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.